1-30 year of age
Have a solid tumors or leukemia that returned or did not respond to previous treatment
Have a primary CNS tumor
Have uncontrolled infection

18 years and older
Hidradentitis Suppurativa diagnosis for 3 months
Normal skin participants
Patients who are Pregnant
Normal skin participants do not have an autoimmune disease
Participants who do not want to have any of the lesion sampling performed

Voluntarily able to provide consent
Diagnosis of HAE Type I or Type II
Able to use a mobile device for data collection in the study
Participation in any interventional clinical trial at the time of enrollment
Unable to provide consent
Investigator believes patient is not a suitable candidate for the study

Have diagnosis of relapsing multiple sclerosis (RMS)
Have experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to injectable disease-modifying drug treatment
Patients who do not have relapsing multiple sclerosis (RMS)
Patients who are doing well on injectable disease-modifying drugs
Patients who have previously been treated with cladribine in any form
Pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during study

People who have a history of hidradenitis suppurativa
Seen at Penn State Health within the past year
18 years of age or older
Can read/write in English
Have access to the internet
Those who do not meet inclusion criteria

Histologic or cytologic evidence of advanced or metastatic biliary tract cancer including cholangiocarcinoma (intra-hepatic or extra-hepatic bile ducts), ampullary carcinoma, and gallbladder carcinoma.
Evidence of recurrent, locally advanced, or metastatic disease.
Progressed following or intolerant to one or more line of systemic therapy.
Presence of at least 1 lesion that is measurable or evaluable using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate organ function, as evidenced by the laboratory parameters noted in Study Eligibility.
Ongoing or active infection requiring systemic antibiotics.
History of previous venous thromboembolic events.
Uncontrolled hypertension despite adequate therapy (i.e., systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 90 mm Hg found on 2 separate occasions separated by 1 week).
Diabetes mellitus and occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to the first dose of study drug.
Active second malignancy other than curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or other cancers with no known active disease in the 3 years prior to enrollment.

Be at least 18 years of age
Understand English
Have normal or normal-corrected vision
Can use standard computer monitor, a mouse, and a game controller
Have visual deficiencies where the person is unable to identify the graphical images on a computer monitor from 20” away
Require use of non-standard graphical interfaces or manipulation devices

18 years or older
Karnofsky Performance Status of at least 70
advanced or metastatic renal carcinoma
No prior systemic therapy
No active brain metastases
Use of an investigational agent or an investigational device within 28 days of randomization
autoimmune disease
History of organ or tissue transplant
Prior major surgery or radiotherapy within 14 days
Any tumor invading the major blood vessels

Over age 18
No food allergies
English Speaker
Under age 18
Food allergies
Non-English Speakers

55-75 years old
Non-smoker
BMI between 18.5 – 35 kg/m2
Systolic BP > 160 mmHg or diastolic BP > 100 mmHg
Fasting glucose > 126 mg/dL
Use of cholesterol/lipid-lowering medications
Use of anti-hypertensive medications
Use of glucose lowering medications

Age 18-30
Right-handed
Native speaker of English
At least a high school education
History of neurogenic or psychiatric illness
Pacemaker or other metal implant
Claustrophobia
Medications that affect cognition

Type I or II HAE
Used androgen therapy for prophylaxis of HAE episodes in past 12 months
Greater than or equal 40 kg
Access to appropriate rescue medication for HAE attacks
Pregnant, breastfeeding, or planned pregnancy
Prior enrollment in BCX 7353 study
Known family history of sudden cardiac death

Patients must have histologically proven, T2-T4a N0M0 urothelial carcinoma of the bladder within 70 days prior to randomization.
Patients must undergo radiological staging within 70 days prior to randomization. Imaging of chest, abdomen, and pelvis must be performed using CT or MRI. Patients must not have evidence of T4bN1-3 disease.
Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and kidney function meets criteria specified.
Female patients of childbearing potential must have a serum pregnancy test prior to randomization.
Patients must be ≥ 18 years of age.
Patient must not have received any systemic chemotherapy for their bladder cancer.
Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.
Patients must not have a major surgical procedure within 28 days prior to randomization.
Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation.
Patients must have adequate bone marrow function as evidenced by all of the following: ANC ≥ 1,500/microliter (mcL); platelets ≥ 100,000/mcL; Hemoglobin ≥ 9 g/dL. These results must be obtained within 28 days prior to randomization.

Age 18-75
Forced vital capacity ≥ 70% predicted
ALS symptom onset within 3 years
Undergoing treatment for cancer
Pregnancy or lactation
Hereditary fructose intolerance
Unable to take medications orally
History of hypersensitivity to edaravone

Between age of 4.5-6.0 years-old
No food allergies
Taking medication that can affect taste or appetite

At least 18 years of age.
Currently living in Centre County, PA.
Expect to continue living in Centre County, PA (through at least Sept 2020)
Capable of providing your own informed consent.
No additional exclusion criteria beyond those required for inclusion.

Confirmed diagnosis of CML ≥ 18 months from diagnosis
Current concomitant treatment with TKI therapy (Imatinib, Dasatinib, Nilotinib or Bosutinib; excluding Ponatinib)
BCR-ABL PCR at stable molecular disease (e.g. MMR stable but not CMR) or b. Hematologic remission (HR) but no MMR
Stable molecular response defined as 2 sequential BCR-ABL levels done in the same lab with less than ½ log reduction of BCR-ABL (BA)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score more than or equal to 3
Current malignancy requiring active treatment
Active infection requiring antibiotic treatment
Known HIV, Hepatitis B, or Hepatitis C infection
Known symptomatic congestive heart failure (CHF), unstable angina or cardiac arrhythmia
Current concomitant use of NSAIDs (including Aspirin) or COX-1; a washout period of 4 weeks prior to enrollment is permitted

Adults age 18 and older
Adults who live in a household with a child under the age of 18
Adult who are fluent in English
Individuals who can read and respond to written closed and open-ended survey questions electronically
Individuals who live in the United States
Individuals under the age of 18
Individuals who do not reside in a household with a child under the age of 18
Individuals who are not fluent in English
Individuals with poor reading comprehension or are otherwise limited in their ability to read and respond to survey questions.
Individuals who do not currently live in the United States

Over the age of 18
Monolingual speaker of English OR
Bilingual speaker of English and at least one other language
Normal hearing
Right-handed
Under the age of 18
Does not speak English
Hearing loss
History of head injury, stroke, TBI, or seizure

Between 18
•25 years old
Has a Tumblr account for a celebrity or fictional character
Younger than 18 years old
Older than 25 years old
Does not have a Tumblr account for a celebrity or fictional character

AML with FLT3 mutation status (includes signal ratio)
Verified confirmation that blasts are myeloid
Verified NPM1 mutation status
Must have an ECOG performance status of 0-3
Must have adequate organ function as measured by criteria
May not have M3 AML
May not have known active Central Nervous System (CNS) leukemia
Not a woman of childbearing potential (WOCBP) or who agrees to follow the contraceptive guidance
May not have a history of Long QT Syndrome
May not have evidence of uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, or congestive heart failure

Pathologically documented unresectable melanoma, American Joint Committee on Cancer (AJCC) version 8, Stage III or IV
Subjects must be refractory to anti-PD-1 monoclonal antibodies (pembrolizumab or nivolumab either as monotherapy or in combination with other approved checkpoint inhibitors or targeted therapies according to their approved label
Resolution/improvement of anti-PD1 mAb-related AEs (including immune related AEs; irAEs) back to Grade 0-1
BRAF V600 mutation-positive melanoma could have received standard of care targeted therapy for advanced or metastatic disease
Has a performance status of 0 or 1 on the ECOG Performance Scale
Subject has disease that is suitable for local therapy administered with curative intent
Clinically active CNS metastases
Subject with a diagnosis of uveal melanoma
Subject who had an allogenic tissue/solid organ transplant
Subjects with electronic pacemakers or defibrillators

Females ages 18-45 years at the time of enrollment
Diagnosed with endometriosis by surgical diagnosis with direct visualization and/or histopathologic confirmation of endometriosis
Women that are pregnant, breastfeeding or trying to conceive
Women with chronic daily opioid use ( > 14 days / month)
Women that are currently using Cannabis based products
Non-English speaking or inability to read and understand English

Has a diagnosis of HCC confirmed by radiology, histology, or cytology
Has HCC localized to the liver without portal vein thrombosis, and not amenable to curative treatment such as resection, ablation, or liver transplant.
Has at least one measurable HCC lesion based on RECIST 1.1,
Has an ECOG performance score of 0 to 1
Has a predicted life expectancy of >3 months.
Is currently a candidate for liver transplantation.
Has had esophageal or gastric variceal bleeding within the last 6 months.
Has clinically apparent ascites on physical examination that is not controlled with medication
Has had clinically diagnosed hepatic encephalopathy in the last 6 months unresponsive to therapy.
Has clinically significant hemoptysis from any source or tumor bleeding within 2 weeks prior

healthy males and females
between 21-40 years old
any race or ethnicity
Females who are pregnant or lactating
Smoker
high blood pressure
opiod use
taking amiloride or similar medication

Healthy adults over 18 years old
Normal or corrected-to-normal vision
No other sensory deficits
Adults who experience synesthesia
Minors under the age of 18

Ages 19-24 and 45-79 years
Physically inactive
Able to walk for at least 30 minutes
Obese
Currently participating in planned, structured physical activity
Lost or gained more than 10 lbs in 6 months
Females currently pregnant or breastfeeding
Currently smoking/using tobacco products or have within the past 6 months
Having signs/symptoms or diagnosed with cardiovascular, lung, kidney, metabolic, or mental health disease

Experiencing significant stress related to COVID-19 pandemic
Fluent in English
Current college or university student
Unable to provide informed consent
Under 18 years of age
Not a college or university student
Not fluent in English

18 years or older
English fluency
Consumed at least one alcoholic beverage per week over the past 4 weeks
17 years or younger
Not fluent in English

Fluent in English
Between 18-65 years of age
Free of types I or II diabetes and cardiovascular disease.
Have had no prior diagnosis of cognitive or physical disability, including ADHD, dyslexia, or epilepsy.
Must currently own or have access to a virtual reality system.
Are not fluent in English.
Are outside of the ages of 18-65 years.
Have had prior diagnosis of cognitive or physical disability, including ADHD, dyslexia, or epilepsy.
Are pregnant at the time of testing.
Do not own or have access to a virtual reality system.